Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, noviembre 04
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
CG Oncology Inc
CGON
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$66.00
1.94
3.03%
Últ. Act.: Nov 4, 9:29 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
CG Oncology Financials
CG Oncology (CGON) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 66.67 percent decrease over losses of $(0.54) per share from
Benzinga Newsdesk
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings
CG Oncology (NASDAQ:CGON) reported mixed results for Q1, with losses of 71 cents per share and sales of $1.083 million. Analysts have adjusted price targets.
Avi Kapoor
PRO
CG Oncology Q1 EPS $(0.71) Misses $(0.57) Estimate, Sales $1.083M Beat $493.182K Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.57) by 24.56 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the
Benzinga Newsdesk
CG Oncology Q4 Earnings Report: What Investors Need to Know
Benzinga Insights
PRO
CG Oncology Q4 EPS $(0.51) Beats $(0.59) Estimate, Sales $2.322M Beat $1.641M Estimate
CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 10.87 percent decrease over losses of $(0.46) per share from the
Benzinga Newsdesk
Crude Oil Rises Sharply; US Consumer Sentiment Edges Higher In January
Avi Kapoor
